The GeoMx Digital Spatial Profiler (DSP) is the first platform to provide high-plex and high-throughput spatial profiling of RNA or protein from a single FFPE section, enabling researchers to dissect the complexity of cellular interactions at a local level and facilitating the discovery of novel biomarkers. The GeoMx DSP provides scientists with a complete solution that includes optimized workflows, off-the-shelf validated assays, and integrated data analysis software.
“Over the last two years, we have worked closely with leaders in immuno-oncology to apply Digital Spatial Profiling, and refine the product design for GeoMx DSP. This has resulted in an integrated solution that anticipates and addresses the needs of biomarker researchers, as well as the publication of a rapidly growing body of scientific studies demonstrating the platform’s power,” said
GeoMx DSP allows researchers to rapidly perform large studies by processing up to 20 tissue slides per day. Tissue morphology is established by scanning whole tissue sections at single-cell resolution using bright-field imaging and up to four florescent channels. An intuitive and flexible interface enables pathologists and non-pathologists alike to segment the sample into biologically meaningful regions of interest down to a single cell. Analysis software included with the system helps researchers explore the biology of the tissue section through an interactive browser that maintains a direct connection between tissue images and localized expression profiles.
GeoMx launches with a modular menu of validated consumable panels that initially support immuno-oncology and neuroscience research, and that will expand over time. The initial portfolio will include:
- Six tissue Morphology Kits for region-of-interest selection
- Ten modular Protein Panels spanning 130 protein targets across immuno-oncology (human and mouse) and neuroscience (human) applications
- An RNA Panel that profiles more than 80 targets covering key targets in immuno-oncology (human), including targets that comprise the Tumor Inflammation Signature
At launch, all GeoMx RNA and protein assays are enabled for readout on the
The performance of the digital spatial profiling technology has been demonstrated under the Technology Access Program (TAP) through more than 70 studies completed with more than 50 customers, covering more than 1,000 customer samples. This research has already yielded several peer-reviewed publications, as well as more than a dozen abstracts presented at major scientific meetings.
An event celebrating the GeoMx DSP launch will be held on
About NanoString Technologies, Inc.
For more information, please visit www.nanostring.com.
Vice President, Investor Relations & Corporate Communications
Source: NanoString Technologies, Inc.